CSCO BC 10th Anniversary Tribute · International Edition | Professor Zefei Jiang in Dialogue With Professor Michael Gnant: From SGBCC to CSCO BC—East-West Collaboration Shaping the Future of Breast Cancer Care

CSCO BC 10th Anniversary Tribute · International Edition | Professor Zefei Jiang in Dialogue With Professor Michael Gnant: From SGBCC to CSCO BC—East-West Collaboration Shaping the Future of Breast Cancer Care

During the 2026 National Breast Cancer Conference, Professor Michael Gnant, President of the St. Gallen International Breast Cancer Conference (SGBCC), traveled across continents to participate in the event, further deepening collaboration between SGBCC and the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC).

Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world's leading oncology conferences, the ASCO Annual Meeting serves as a key venue for presenting advances in cancer research and clinical development. This year, Hengrui Pharma presented more than 90 studies spanning multiple tumor types and therapeutic modalities.
ESMO BC International Perspective | Professor François Clément Bidard: SERENA-6 Screening Data Highlight the Value of Continuous ESR1 Mutation Monitoring to Precisely Intercept Progression in HR+ Advanced Breast Cancer

ESMO BC International Perspective | Professor François Clément Bidard: SERENA-6 Screening Data Highlight the Value of Continuous ESR1 Mutation Monitoring to Precisely Intercept Progression in HR+ Advanced Breast Cancer

At the recently concluded ESMO Breast Cancer Congress 2026 (ESMO BC 2026), Professor Matteo Lambertini from IRCCS Ospedale Policlinico San Martino and the University of Genova served as one of the chairs of the session “Breast Cancer in Young Women (BCY) Session – Management of HR+ Breast Cancer in Young Women.” Together with fellow panelists, he participated in in-depth discussions on several key issues surrounding the management of breast cancer in young women.
ESMO BC International Perspective | Professor François Clément Bidard: SERENA-6 Screening Data Highlight the Value of Continuous ESR1 Mutation Monitoring to Precisely Intercept Progression in HR+ Advanced Breast Cancer

ESMO BC International Perspective | Professor François Clément Bidard: SERENA-6 Screening Data Highlight the Value of Continuous ESR1 Mutation Monitoring to Precisely Intercept Progression in HR+ Advanced Breast Cancer

ESR1 mutation is a major mechanism of acquired resistance during first-line endocrine therapy for HR+/HER2− advanced breast cancer. At this year’s ESMO Breast Cancer Congress, Professor François Clément Bidard from Institut Curie presented screening-phase data from the SERENA-6 study (Abstract No. 419RO).
ESMO BC Global Perspective | Professor Neelima Vidula: Pembrolizumab Plus Carboplatin Did Not Improve Disease Control in Advanced Breast Cancer With Chest Wall Disease, but the Search for Durable Responses Continues

ESMO BC Global Perspective | Professor Neelima Vidula: Pembrolizumab Plus Carboplatin Did Not Improve Disease Control in Advanced Breast Cancer With Chest Wall Disease, but the Search for Durable Responses Continues

At the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Neelima Vidula from Massachusetts General Hospital presented the findings of the randomized phase II ICI-CHEST, TBCRC044 study (Abstract No. 425RO), offering important clinical insights into one of the most challenging settings in advanced breast cancer. The study investigated whether adding the PD-1 inhibitor pembrolizumab to standard carboplatin chemotherapy could improve outcomes in patients with advanced breast cancer accompanied by chest wall disease (CWD), a population known for extremely poor prognosis and limited responsiveness to systemic therapy.
ESMO BC Global Perspective | Professor Sibylle Loibl: Insights From the INAVO120 Study—The “Counterintuitive” Association Between Hyperglycemia and Improved Outcomes

ESMO BC Global Perspective | Professor Sibylle Loibl: Insights From the INAVO120 Study—The “Counterintuitive” Association Between Hyperglycemia and Improved Outcomes

At the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Sibylle Loibl from Goethe University Frankfurt presented a post hoc analysis of hyperglycemia in the INAVO120 study. The analysis explored investigator-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), and overall survival (OS) according to whether patients experienced hyperglycemia of any grade.
ESMO BC Global Perspective | Professor Sung-Bae Kim: Rethinking Treatment for Intermediate-Risk HR+ Early Breast Cancer—Could Adjuvant CDK4/6 Inhibitors Replace Chemotherapy?

ESMO BC Global Perspective | Professor Sung-Bae Kim: Rethinking Treatment for Intermediate-Risk HR+ Early Breast Cancer—Could Adjuvant CDK4/6 Inhibitors Replace Chemotherapy?

During the “Adjuvant Therapy for Hormone Receptor-Positive Early Breast Cancer” session at the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Sung-Bae Kim from Asan Medical Center, University of Ulsan College of Medicine, delivered an insightful presentation entitled “Adjuvant CDK4/6 Inhibitors: Could They Replace Chemotherapy for Intermediate-Risk ER+ Early Breast Cancer?” Following the session, Professor Sung-Bae Kim spoke with Oncology Frontier and further elaborated on the key concepts presented in his talk.
Oncology Frontier FM · ESMO BC Special | Professor Lajos Pusztai: Neoadjuvant T-DXd-THP Improves Residual Cancer Burden in HER2-Positive Breast Cancer

Oncology Frontier FM · ESMO BC Special | Professor Lajos Pusztai: Neoadjuvant T-DXd-THP Improves Residual Cancer Burden in HER2-Positive Breast Cancer

At the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Lajos Pusztai from Yale University presented an analysis from the neoadjuvant DESTINY-Breast11 (DB-11) study. The results demonstrated that the T-DXd-THP regimen not only increased the pathological complete response (pCR) rate to 67.3%, but also significantly shifted the overall distribution of residual cancer burden (RCB) toward lower categories.
Oncology Frontier FM · ESMO BC Special | Professor Heather Parsons: ctDNA Monitoring for Predicting Recurrence in ER-Positive Early Breast Cancer—Promising Potential, but Evidence Still Needed

Oncology Frontier FM · ESMO BC Special | Professor Heather Parsons: ctDNA Monitoring for Predicting Recurrence in ER-Positive Early Breast Cancer—Promising Potential, but Evidence Still Needed

Liquid biopsy technologies are rapidly advancing, and circulating tumor DNA (ctDNA) monitoring has demonstrated enormous potential in precision treatment for breast cancer. During the Educational Session “Adjuvant Therapy for ER-Positive Breast Cancer” at the ESMO Breast Cancer Congress (ESMO BC), Professor Heather Parsons from the Fred Hutchinson Cancer Center delivered a presentation entitled “The Role of ctDNA Monitoring in ER+ Early Breast Cancer: Could It Change Practice?”
Where Is the Next Breakthrough in Colorectal Cancer? Prof. Toh Han Chong Shares His Insights

Where Is the Next Breakthrough in Colorectal Cancer? Prof. Toh Han Chong Shares His Insights

On March 21, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou, Zhejiang Province. Hosted by the Second Affiliated Hospital of Zhejiang University School of Medicine, the event brought together top-tier colorectal surgery experts from across China for in-depth discussions on key topics, including colorectal cancer liver metastasis, peritoneal metastasis, para-aortic lymph node metastasis, locally advanced rectal cancer, combined organ resection, and the association between obesity and colorectal cancer. Prof. Toh Han Chong from the National Cancer Centre Singapore (NCCS) attended the conference.